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ABSTRACT
SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor 
prognosis ovarian tumours, and preclinical studies have supported the use of targeted 
SRC inhibitors in the treatment of this disease. The SAPPROC trial investigated the 
addition of the SRC inhibitor saracatinib (AZD0530) to weekly paclitaxel for the 
treatment of platinum resistant ovarian cancer; however, this drug combination did 
not provide any benefit to progression free survival (PFS) of women with platinum 
resistant disease. In this study we aimed to identify mechanisms of resistance to SRC 
inhibitors in ovarian cancer cells. Using two complementary strategies; a targeted 
tumour suppressor gene siRNA screen, and a phospho-receptor tyrosine kinase 
array, we demonstrate that activation of MAPK signalling, via a reduction in NF1 
(neurofibromin) expression or overexpression of HER2 and the insulin receptor, can 
drive resistance to AZD0530. Knockdown of NF1 in two ovarian cancer cell lines 
resulted in resistance to AZD0530, and was accompanied with activated MEK and 
ERK signalling. We also show that silencing of HER2 and the insulin receptor can 
partially resensitize AZD0530 resistant cells, which was associated with decreased 
phosphorylation of MEK and ERK. Furthermore, we demonstrate a synergistic effect of 
combining SRC and MEK inhibitors in both AZD0530 sensitive and resistant cells, and 
that MEK inhibition is sufficient to completely resensitize AZD0530 resistant cells. This 
work provides a preclinical rationale for the combination of SRC and MEK inhibitors 
in the treatment of ovarian cancer, and also highlights the need for biomarker driven 
patient selection for clinical trials.
www.impactjournals.com/oncotarget/                      Oncotarget, 2018, Vol. 9, (No. 4), pp: 4722-4736
INTRODUCTION
Epithelial ovarian cancer (EOC) is the fifth most 
common cancer affecting women in the UK, and due to a 
lack of indicative symptoms, the majority of women will 
be diagnosed in the late stages (III-IV) of disease [1]. This 
late diagnosis results in poor prognosis and high mortality 
rates, thus this disease has been dubbed the silent killer 
[2, 3], with less than 35% of women surviving their 
disease for more than ten years [4] Survival rates have 
only marginally improved over the last 40 years, largely 
due to the heterogeneous biology that underpins the 
development of this disease, as well as the poor ability to 
detect the presence of EOC in early stages. Although many 
targeted therapies have been investigated in the treatment 
of EOC, the majority have failed to show any clear clinical 
benefit and upfront treatment remains debulking surgery 
followed by a platinum and taxane based chemotherapy 
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regime. Following initial chemotherapy, the majority 
will relapse and eventually succumb to platinum/taxane 
resistant disease [5].
SRC is a non-receptor tyrosine kinase which has 
proven to be an important oncogene in various cancer 
types including breast [6], colorectal [7–9] and EOC 
[10, 11]. SRC has been reported to be overexpressed 
and activated in late stage poor outlook EOC [10] and 
in vivo xenograft data has shown that inhibition of SRC 
activity reduces tumour growth [11]. SRC activity has 
also been implicated in resistance of ovarian cancer cells 
to anti-estrogen therapies, and a combination of the SRC 
inhibitor saracatinib (AZD0530) and fluvestrant resulted 
in increased cell cycle arrest and decreased survival of 
ovarian cancer cells [12]. Furthermore, SRC has also been 
identified as a potential driver of resistance to paclitaxel 
in ovarian cancer cells, and SRC inhibition enhances 
the antitumour and antiangiogenic effects of paclitaxel 
[13–15]. These findings have supported the use of SRC 
inhibitors for the treatment of ovarian cancer in the clinic, 
and a number of phase I trials have shown the efficacy 
of SRC inhibitors to reduce phosphorylation of SRC 
(Tyr416) in a safe and tolerable manner in combination 
with platinum and taxane chemotherapy [16, 17]. In light 
of these findings, saracatinib (AZD0530), a potent kinase 
inhibitor with selective action against SRC was studied 
in combination with weekly paclitaxel in the phase II 
SAPPROC trial (NCT01196741) for women with recurrent 
platinum resistant EOC [18]. Surprisingly this study 
reported that the addition of AZD0530 to weekly paclitaxel 
did not improve progression free survival (PFS) [18].
Multiple studies have identified a number of 
mechanisms of resistance to inhibitors of the SRC 
pathway including activation of the mTOR pathway [19], 
suppression of autophagy [20] and secondary mutations in 
DDR, as well as loss of the tumour suppressor gene NF1 
[21]. It has also been reported that PTTG1 expression is 
predictive of sensitivity in ovarian cancer cell lines to SRC 
inhibition with saractinib (AZD0530) [22]. However this 
work has not been performed in ovarian cancer models 
of acquired resistance to SRC inhibitors. We aimed to 
identify potential mechanisms of resistance to the SRC 
inhibitor AZD0530 in EOC by using two complementary 
screening methods and novel models of acquired 
resistance to AZD0530, and identified MAPK signalling 
as a potential predictive biomarker for SRC inhibitor 
resistance and for combination drug therapy. 
RESULTS
A targeted tumour suppressor gene siRNA screen 
identifies loss of NF1 as a mediator of AZD0530 
resistance
A customized siRNA library targeting 178 tumour 
suppressor genes (TSG) (Supplementary Table 1) was 
used to identify those tumour suppressors whose knock-
down confers resistance to AZD0530. Human foreskin 
fibroblast (HFF) cells were used for screening purposes as 
they are less likely to contain any pre-existing alterations 
in TSGs [23]. An IC50 for AZD0530 in these cells was 
determined as 10 μM, which resulted in a reduction 
in the levels of phosphorylated FAK (Supplementary 
Figure 1A), a downstream target of SRC kinase activity. 
Following transfection of HFF cells with the siRNA library, 
and treatment with either DMSO or 10 μM AZD0530, 
cell viability was measured 72 hours later (Figure 1A). 
Target genes were defined as resistant hits when each of 
the 3 independent siRNAs had a robust z-score greater or 
less than ±1 respectively. We identified 53 resistant hits 
(Supplementary Table 2). To select potential hits which are 
relevant to ovarian cancer, we cross- referenced the list of 
resistant hits with the most frequently occurring mutations 
in high-grade serous ovarian cancer (HGSOC) [24]. We 
identified that knockdown of NF1, BRCA1 and TP53 lead 
to decreased sensitivity to AZD0530, and were one of the 
most frequently mutated genes in HGSOC. To validate 
the findings from the library screen we independently 
knocked down NF1, BRCA1 and TP53 in HFF cells using 
an alternative siRNA sequence and investigated sensitivity 
to AZD0530 by cell count after 10 days (Supplementary 
Figure 1B). RNAi mediated knockdown of BRCA1 and 
TP53 did not result in loss of sensitivity to AZD0530 
(Supplementary Figure 1B), while, NF1 knockdown resulted 
in decreased sensitivity to AZD0530 compared to a negative 
control siRNA, with an increase in IC50 from 0.16 μM to 
0.35 μM (fold change 2.2) (Supplementary Figure 1B). 
To further investigate whether loss of BRCA1 or P53 
expression resulted in decreased sensitivity to AZD0530, we 
tested isogenic cell lines MDA-MB-436-E.V (empty vector) 
and matched MDA-MB-436 +BRCA1 [25], and MCF10A 
parental cells and matched MCF10A P53–/– [26]. Colony 
formation assay showed that the BRCA1 mutant MDA-MB-
436-E.V cell line was in fact more sensitive to AZD0530 
than MDA-MB-436 + BRCA1 cells further demonstrating 
that loss of BRCA1 does not result in resistance to SRC 
inhibition (Supplementary Figure 2C). Furthermore, colony 
formation assay showed that MCF10A breast cells which 
have TP53 knockout, did not exhibit decreased sensitivity 
to SRC inhibition compared to parental MCF10A P53 WT 
cells. NF1 was therefore selected for further investigation in 
two ovarian cancer cell lines. 
To select the most appropriate cell line models, we 
tested the sensitivity of a panel of ovarian cancer cells 
to AZD0530 by colony formation assay. TOV112D and 
IGROV1 EOC cells displayed high sensitivity to SRC 
inhibition with AZD0530, with IC50s of 230 nM and 
370 nM respectively, indicating a reliance on SRC signaling 
for survival and growth (Supplementary Figure 2). 
NF1 was silenced in both TOV112D and IGROV1 
cells using two independent siRNAs, and sensitivity to 
AZD0530 assessed by a colony formation assay. Consistent 
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with a role in resistance to AZD0530, knockdown of NF1 
with both siRNAs resulted in a significant increase in the 
IC50 for both TOV112D cells, from 0.035 μM to 0.29 μM 
(p < 0.0001) and 0.083 μM (p = 0.043) (fold change 
8.29, 2.37 respectively) and IGROV1 cells, from 0.01 μM 
to 0.17 μM (p < 0.0001) and 0.026 μM (p = 0.028) (fold 
change 16.5, 2.56 respectively) (Figure 1B). The protein 
product of NF1, neurofibromin, inhibits mitogen-activated 
protein kinase (MAPK) dependent proliferation and 
differentiation pathways [27, 28]. As expected, siRNA 
mediated knockdown of NF1 using two siRNAs in 
TOV112D and IGROV1 cells led to increased MEK and 
ERK phosphorylation in both TOV112D and IGROV1 
cells (Figure 1C), indicating MAPK activation.
Saracatinib (AZD0530) resistant ovarian 
cell lines exhibit increased HER2 and insulin 
receptor expression
To complement the siRNA screen, we used a 
further strategy to investigate mechanisms of resistance 
to AZD0530. To do this we generated AZD0530 resistant 
EOC cell lines in vitro and used these for screening 
purposes. TOV112D cells were cultured in AZD0530 
for 6 months after which resistance was confirmed by a 
significant increase in colony formation assay following 
treatment with AZD0530 (Figure 2A). TOV112D 
resistant cells (TOV112D-RES), exhibited a 165 fold 
increase in their IC50 for AZD0530 compared to the 
parental cell line (TOV112D-WT), from 0.11 μM to 
18 μM (p < 0.0001) (Figure 2A). These resistant cells 
were also shown to have a significant increase in survival 
by colony formation assay following RNAi mediated 
SRC knockdown compared to TOV112D-WT cells 
(p = 0.0055, p = 0.019) (Supplementary Figure 3A), 
thus demonstrating no requirement for SRC activity. 
Next we asked if AZD0530 was still able to inhibit SRC 
activity in these resistant cells. Following treatment with 
AZD0530 there was a decrease in levels of phosphorylated 
SRC (Tyr416) and FAK (Tyr925) in both TOV112D-
WT and TOV112D-RES cells, indicating that the drug 
was on-target (Supplementary Figure 3B). Interestingly, 
we also observed a decrease in the levels of total SRC 
protein expression in TOV112D-RES cells compared 
to TOV112D-WT cells (Supplementary Figure 3A and 
3B). Combined with the fact that AZD0530 was still 
preventing phosphorylation of FAK Y295, this indicates 
that TOV112D-RES cells no longer require SRC activity 
or expression for survival and growth, and activation of 
alternative survival pathways may therefore be driving 
drug resistance. 
A second AZD0530 resistant ovarian cell line 
was generated by culturing IGROV1 cells in AZD0530 
(IGROV1-RES). IGROV1-RES cells exhibited a 5 fold 
increase in their IC50 for AZD0530 compared to their 
parental cell line (IGROV1-WT) from 0.087 μM to 
0.44 μM (p < 0.0001) (Supplementary Figure 3D) and 
similarly treatment of both IGROV1-WT and IGROV1-
RES cells with AZD0530 resulted in a decrease in the 
phosphorylation of both SRC (Tyr416) and FAK (Tyr925) 
(Supplementary Figure 3E). 
Since receptor tyrosine kinases (RTKs) are important 
mediators of downstream signaling pathways and have 
also been implicated in resistance to both conventional 
chemotherapies as well as targeted agents [29–32], we 
investigated whether RTK expression was associated 
with saracatinib resistance. We used TOV112D-WT 
and TOV112D-RES cells to screen a panel of 49 RTKs 
and identified a significant increase in the activation of 
the HER2 receptor and insulin receptor in the AZD0530 
resistant cells (Figure 2B, Supplementary Figure 3C). These 
findings were confirmed by western blotting, whereby 
TOV112D-RES cells exhibited increased phosphorylation 
and expression of both HER2 and the insulin receptor, 
and was accompanied with increased phosphorylation of 
MEK and ERK, indicating activation of MAPK signaling, 
compared to TOV112D-WT cells (Figure 2C). Similarly, an 
increase in expression and phosphorylation of HER2 and the 
insulin receptor accompanied by activated MEK and ERK 
signaling was also demonstrated in IGROV1-RES cells 
compared to IGROV1-WT (Supplementary Figure 3F). 
The insulin receptor is known to exist as two splice 
variants, insulin receptor-A (IR:A) and insulin receptor-B 
(IR:B) [33], where IR:A is preferentially activated by 
IGF-II over insulin, and signals via the MAPK pathway 
to induce mitogenic signaling. We observed a significant 
increase in the mRNA expression of both IR:A (p = 0.007) 
and IR:B (p = 0.041) as well as a significant increase in 
the mRNA levels of the IR:A ligand IGF-II (p = 0.042) 
in the TOV112D-RES cells compared to TOV112D-WT 
cells (Figure 2D). In addition we observed a significant 
increase in the expression of HER2 mRNA (p = 0.0026) in 
TOV112D-RES cells compared to TOV112D-WT.
To investigate if the observed increase in MAPK 
activation was a direct result of increased expression and 
activation of each of these receptors, we silenced each 
receptor using two independent siRNAs in TOV112D-
WT and TOV112D-RES cells. Knockdown of each of 
these receptors resulted in a decrease in MEK and ERK 
phosphorylation in TOV112D-RES, but not in TOV112D-
WT cells, suggesting that the observed increase in MAPK 
activation is a direct consequence of increased HER2 and 
insulin receptor expression (Figure 2E). Interestingly, we 
also observed that siRNA mediated knockdown of HER2 
resulted in decreased expression of insulin receptor levels 
specifically in TOV112D-RES cells, but not in TOV112D-
WT cells. This indicates that HER2 may be driving the 
observed increased expression of the insulin receptor in 
TOV112D-RES cells, and so both of these receptors may 
be working together to drive activation of MAPK signaling, 
and therefore resistance to SRC inhibition (Figure 2E). 
Cooperation of HER2 and the insulin/IGF1R pathway 
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has been previously implicated in resistance to targeted 
therapies, whereby in a model of trastuzumanb resistant 
breast cancer, HER2 and IGF1R form heterodimers, and 
stimulation of IGF1R leads to HER2 phosphorylation in 
resistant cells, but not in sensitive cells [34].
To confirm that the increased expression and 
activation of HER2 and the insulin receptor could account 
for resistance to SRC inhibition, we tested the colony 
formation ability of each cell line in the presence of 
AZD0530 following silencing of both receptors using 
Figure 1: A targeted tumour suppressor gene siRNA screen identifies loss of NF1 as a mechanism of resistance to SRC 
inhibition. (A) siRNA screening method. HFF cells were reverse transfected with 3 independent siRNAs targeting 178 tumour suppressor 
genes and 24 hours later were treated with either DMSO control or 10 uM AZD0530. Cell viability was recorded 72 hours later. Scatter plot 
showing distribution of robust z-scores for tumour suppressor gene siRNA screen. Positive scores indicate potential mediators of resistance 
to AZD0530, while negative scores indicate potential mediators of sensitivity to AZD0530. Each siRNA targeting NF1 is highlighted 
in red. Pathway analysis and gene ontology identified a list of genes which were involved in the regulation of protein kinase activity. 
(B) Colony formation assay assessing the sensitivity of TOV112D and IGROV1 cells to increasing concentrations of AZD0530 following 
transfection with negative control siRNA, or two independent siRNAs targeting NF1. IC50 values are shown. (C) Representative western 
blot analysis showing levels of NF1, phospho-MEK (Ser217/222), phospho-ERK (Thr202/Tyr204) following transfection of TOV112D 
and IGROV1 with negative control siRNA, and two independent siRNAs targeting NF1. Levels of total MEK and ERK are also shown, 
and vinculin levels are shown as a loading control. Western blotting analysis is representative of at least 3 independent biological replicates. 
P values are shown and were calculated using extra-sum of squares F-test. Data represented as mean ± S.E.M n ≥ 3. 
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Figure 2: A phospho-RTK array identifies activation of HER2 and insulin receptor as mediators of resistance to 
AZD0530. (A) 10 day colony formation assay assessing sensitivity of TOV112D-WT and TOV112D-RES cells to increasing concentrations 
of AZD0530. IC50 values are shown. (B) Relative pixel intensity of levels of phospho-HER2 and phospho-Insulin receptor in phospho-
RTK array (C) Representative western blot analysis showing levels of phosphorylated and total HER2 protein expression, phosphorylated 
insulin/IGF1R and total levels of the insulin receptor, and phosphorylated MEK (Ser217/221) and ERK (Thr202/Tyr204) in TOV112D 
WT and TOV112D-RES cells. Total MEK and ERK levels are also shown. Vinculin was used as a loading control. (D) Quantitative real-
time polymerase chain reaction (qRT-PCR) analysis of relative mRNA expression of insulin receptor isoform A (IR:A), IGF-2, insulin 
receptor isoform B (IR:B) and HER in TOV112D-WT and TOV112D-RES cells. (E) Representative western blot analysis showing levels 
of total HER2 and insulin receptor protein expression following transient transfection of TOV112D-WT and TOV112D-RES cells with 
two siRNAs targeting the insulin receptor and HER2. Levels of phosphorylated MEK (Ser217/221) and ERK (Thr202/204) are shown, 
as well as total levels of MEK and ERK. Vinculin was used as a loading control. (F) Colony formation assay showing sensitivity of 
TOV112D-WT and TOV112D-RES cells to increasing concentrations of AZD0530 following treatment with two siRNAs targeting the 
insulin receptor or the HER2 receptor. IC50 values are shown. P values are shown and were calculated using extra-sum of squares F-test 
for drug sensitivity assays. Western blotting analysis is representative of at least 3 independent biological replicates. Statistical significance 
comparing phospho-RTK and gene expression data was calculated using an unpaired students t-test. * = p < 0.05 **= p < 0.01 ***p < 0.001. 
Data represented as mean ± S.E.M n ≥ 3.
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two siRNAs. Silencing of HER2 and the insulin receptor 
did not result in increased sensitivity of TOV112D-WT 
cells to AZD0530, however, silencing of both of these 
receptors increased sensitivity of TOV112D-RES cells 
to AZD0530, compared to negative control transfected 
cells. This led to a decrease in the IC50 of TOV112D-RES 
cells from 2.39 μM to 1.180 μM (p = 0.027), 1.13 μM 
(p = 0.025), 1.037 μM (p = 0.026) and 0.29 μM 
(p < 0.0001) following transfection with a negative control 
siRNA, and two siRNAs targeting the insulin receptor 
and HER2, respectively (Figure 2F). Notably, silencing 
of either HER2 or the insulin receptor alone resulted in 
a partial rescue in sensitivity of TOV112D-RES cells to 
AZD0530, suggesting that these receptors act in parallel 
to confer resistance.
SRC and MEK act in parallel pathways
To further validate our findings from the TSG siRNA 
screen and the phospho-RTK array, we generated stable 
SRC knockdown cell lines to represent a cell population 
that can survive in the absence of SRC signaling, thereby 
modeling resistance to SRC inhibition. We transfected 
TOV112D cells with a SRC targeted shRNA, and isolated 
clones. We examined the expression of NF1, the insulin 
receptor and HER2 in the stable SRC knockdown cells. 
Interestingly, we found that 5 of the stable SRC knockdown 
clones demonstrated decreased expression of the NF1 gene 
product neurofibromin. Furthermore, each of these clones 
also exhibited increased phosphorylation and expression 
of both the HER2 and insulin receptor (Figure 3A). 
Each of the SRC knockdown clones exhibited increased 
MAPK signaling, with increased levels of ERK 
phosphorylation compared to the shScrambled control cell 
lines (Figure 3A), supporting its role in promoting cellular 
survival in the absence of SRC signaling. 
To confirm that stable knockdown of SRC was in 
fact a model of resistance to SRC inhibition, we tested 
sensitivity of two SRC knockdown clones to AZD0530. 
We selected TOV112D-shSRC4 and TOV112D-shSRC5 
as they demonstrated the most prominent knockdown of 
SRC, loss of NF1 expression, and the biggest increase in 
insulin receptor and HER2 activation and expression. We 
found that TOV112D-shSRC4 and TOV112D-shSRC5 
exhibited decreased sensitivity to SRC inhibition with 
AZD0530 by colony formation, with an increase in IC50 
from 0.078 μM in the shScrambled cells to 2.3 μM (p < 
0.0001) for shSRC4 and 0.6 μM for shSRC5 (p < 0.0001) 
(Figure 3B).
In order to confirm the requirement for MAPK 
signaling in the SRC knockdown cell lines, we tested 
sensitivity to the MEK inhibitor trametinib. Consistent 
with a role for MAPK signaling in promoting survival, two 
SRC knockdown clones exhibited increased sensitivity to 
MEK inhibition with a decrease in the IC50 from 0.36 μM 
in the shScrambled cells to 0.0029 μM for shSRC 4 
(p < 0.0001) and 0.071 μM for shSRC 5 (p < 0.0001), 
resulting in a fold change in the IC50 of 12.2 and 
5 respectively (Figure 3C). 
Given the observed increased sensitivity of the stable 
SRC knockdown clones to MEK inhibition with trametinib, 
we then tested the requirement for MEK activity for 
the survival of the AZD0530 resistant TOV112D-RES 
cell line. Colony formation assay demonstrated that 
TOV112D-RES cells were significantly more sensitive to 
MEK inhibition compared to TOV112D-WT cells, with 
a decrease in the IC50, from 0.041 μM to 0.0053 μM 
(p < 0.0001) respectively (fold change 7.8), suggesting a 
reliance on MEK signalling in the AZD0530 resistant line 
(Figure 3D). 
We then investigated the acute effect of SRC inhibition 
with AZD0530 on MEK signalling. Following treatment of 
TOV112D cells with 1 μM AZD0530 over a 24 hour time-
course, we observed decreased phosphorylation of SRC 
(Tyr416). Interestingly, this coincided with an increase in 
phosphorylation of ERK (Th202/Tyr204) again supporting 
parallel functions of the SRC and MAPK pathways (Figure 
3E). We then asked if this was a compensatory relationship, 
and inhibited MEK in TOV112D cells with GSK1120212 
over the same time course. We observed a decrease in 
ERK phosphorylation (Th202/Tyr204) and a concomitant 
increase in SRC phosphorylation (Tyr416) (Figure 3E). 
Together these data suggest that the SRC and MAPK 
pathway are parallel and compensatory, and inhibition of 
one leads to activation of the other, allowing for cell survival 
and proliferation, resulting in drug resistance.
Dual inhibition of saracatinib (AZD0530) and 
trametinib (GSK1120212) synergistically inhibits 
colony formation in saracatinib resistant cells
To investigate the therapeutic potential of combining 
SRC and MEK inhibitors we treated both the TOV112D 
and IGROV1 cells, and their respective AZD0530 resistant 
counterparts with increasing concentrations of AZD0530, 
either as a single agent, or in combination with the 
100nM MEK inhibitor GSK1120212. Colony formation 
was assessed after a 10 day period, and for combination 
treatments, survival was calculated as a percentage of 
the effect of 100 nM GSK1120212, to demonstrate any 
synergistic effects. The combination of GSK1120212 and 
AZD0530 resulted in a significant decrease in colony 
formation of both TOV112D-WT and TOV112D-RES 
cells compared to AZD0530 treatment alone. This resulted 
in a decrease in IC50 from 0.1247 μM to 0.0095 μM 
(p < 0.0001 fold change 26) for TOV112D-WT cells, 
and a decrease in IC50 from 1.503 μM to 0.0306 μM 
(p < 0.0001) (fold change 49) for TOV112D-RES cells 
(Figure 4A). Similarly, the combination of GSK1120212 
with AZD0530 resulted in a significant decrease in 
survival of the second in vitro derived AZD0530 resistant 
cell line, IGROV1-RES, and its matched parental 
cell line, IGROV1-WT, compared to treatment with 
AZD0530 alone. This resulted in a decrease in the IC50 
Oncotarget4728www.impactjournals.com/oncotarget
Figure 3: SRC and MEK act as parallel and compensatory pathways. (A) Representative western blot analysis of 5 stable 
SRC knockdown clonal cell populations and a scrambled shRNA control cell population (shScrambled) generated in TOV112D cells. 
NF1, phospho-insulin receptor/IGF1R, phopsho-HER2 and phospho-ERK levels are shown. Total levels of the insulin receptor, HER2 
and ERK are also shown. Vinculin expression was used as a loading control. (B) 10 day colony formation assay showing sensitivity 
of TOV112D shScrambled, TOV112D shSRC 4 and TOV112D shSRC 5 to increasing concentrations of AZD0530. IC50 values are 
shown (C) 10 day colony formation assay showing sensitivity of TOV112D shScrambled, TOV112D shSRC 4 and TOV112D shSRC 5 to 
increasing concentrations of trametinib (GSK1120210) IC50 values are shown. (D) 10 day colony formation assay assessing sensitivity of 
TOV112D-WT and TOV112D-RES cells to increasing concentrations of GSK1120212. IC50 values are shown. (E) Representative western 
blot analysis showing levels of ERK and SRC phosphorylation following treatment of TOV112D cells with either 1 μM saracatainib 
(AZD0530) for 3, 6, 12, and 24 hours. Total levels of SRC and ERK are also shown. Beta-actin expression was used as a loading control. 
(F) Representative western blot analysis showing levels of ERK and SRC phosphorylation following treatment of TOV112D cells with 
1μM trametinib (GSK1120212) for 3, 6, 12, and 24 hours. Total levels of SRC and ERK are also shown. Beta-actin expression was used as 
a loading control. Western blotting analysis is representative of at least 3 independent biological replicates. P values are shown and were 
calculated using extra-sum of squares F-test. Data presented represents mean ± S.E.M n ≥ 3.
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from 0.18 μM to 0.026 μM (p = 0.034 fold change 4.5) 
for IGROV1-WT cells, and a decrease in IC50 from 
1.28 μM to 0.016 μM (fold change 80) for IGROV1-RES 
cells (p < 0.0001) (Figure 4B). The greater fold change in 
the IC50 of both AZD0530 resistant cell lines suggested a 
reliance on MAPK signalling for survival in the presence 
of SRC inhibition in TOV112D-RES and IGROV1-RES 
cells compared to their parental cell lines. To confirm a 
synergistic effect of the combination of MEK inhibition 
and SRC inhibition, combination index (CI) values were 
calculated (Figure 4C). The combination of AZD0530 and 
GSK1120212 was found to be synergistic in TOV112D-
WT, TOV112D-RES cells, IGROV1-WT and IGROV1-
RES cells. However, increased levels of drug synergy were 
observed in TOV112D-RES cells, (CI values ranging from 
0.001 to 0.03) when compared to TOV112D-WT cells (CI 
values ranging from 0.486 to 1.350) treated with the same 
combination of AZD0530 and GSK1120212 indicating 
a greater reliance on MEK activation for survival of 
AZD0530 resistance cells in the presence of the inhibitor. 
DISCUSSION
The use of targeted therapies in the treatment 
of solid malignancies is often limited by the rapid 
development of drug resistant disease, hence there is a 
drive in the field of molecular oncology towards a better 
understanding of potential mechanisms of resistance to 
targeted small molecule inhibitors [35]. 
This phenomenon of rapid acquired or intrinsic 
resistance may explain the findings of the SAPPROC 
trial (NCT01196741), which investigated the use of the 
SRC inhibitor saracatinib (AZD0530) in combination with 
weekly paclitaxel, for the treatment of platinum resistant 
ovarian cancers. Despite promising preclinical studies 
which highlight the potential to target SRC in ovarian 
cancer, and provide a clear rationale for this clinical trial, 
results showed no benefit to progression free survival 
(PFS) when combining saracatinib (AZD0530) with 
weekly paclitaxel in this patient population [18]. We set 
out to investigate potential mechanisms of resistance to the 
SRC inhibitor saracatinib (AZD0530) in ovarian cancer, 
with the aim to highlight potential combination therapies 
and treatment stratification markers for SRC inhibitors in 
this disease. 
By using complementary screening approaches, 
a targeted tumour suppressor gene siRNA screen and a 
phopsho-RTK array, we have shown that loss of NF1 
(neurofibromin) expression and increased activation and 
expression of both the HER2 receptor and the insulin 
receptor lead to resistance to saracatinib, via increased 
activation of the MAPK pathway (Figure 5). 
Using a targeted tumour suppressor gene siRNA 
screen, we aimed to identify genes whose loss resulted 
in decreased sensitivity to AZD0530, hence the siRNA 
screen was designed to specifically identify mediators 
of resistance. To enrich for selection of mediators of 
resistance, we used an IC50 for AZD0530, and in doing so, 
we did not identify any genes whose knockdown resulted 
in increased sensitivity to AZD0530. The siRNA screen 
identified NF1 loss as a mediator of resistance to AZD0530. 
Loss of NF1 has been reported to result in resistance to 
various targeted tyrosine kinase inhibitors in a number of 
settings, including BRAF-mutant melanoma and EGFR-
mutant lung cancer [36–38]. Consistent with our findings, 
mutation and subsequent loss of the tumour suppressor 
function of NF1 has been reported in lung cancer cells 
which have acquired resistance to the SRC inhibitor 
dasatinib, and this was associated with active RAS-MAPK 
signalling [21]. Here, we have demonstrated that reduction 
in the expression of NF1 in two ovarian cancer cell lines 
results in activated MEK and ERK signalling, and is 
associated with decreased sensitivity to SRC inhibition. 
Importantly, it has been reported that NF1 is the fourth most 
altered gene in epithelial ovarian cancer [24], highlighting 
the relevance of this genetic alteration when targeting SRC 
in this disease setting. 
By generating in vitro derived saracatinib (AZD0530) 
resistant ovarian cell lines we have demonstrated that 
overexpression and activation of both HER2 and the 
insulin receptor also results in resistance to SRC inhibition. 
Amplification of ErbB2 (HER2) occurs in 28% of ovarian 
cancers [39], representing a potential therapeutic target 
in this subset of ovarian cancer patients. SRC activity 
has previously been linked to resistance to anti-HER2 
therapies, with SRC activation correlating with trastuzumab 
resistance in breast cancer cells, and overexpression of 
an activated mutant form of SRC (Y527F) resulted in 
resistance to trastuzumab-mediated growth inhibition [40]. 
Furthermore, it has previously been shown that saracatinib 
resensitized gastroeosophageal cancer cell lines resistant to 
the HER2 inhibitor lapatinib [41]. 
We have also shown that knockdown of HER2 
results in decreased levels of insulin receptor expression, 
specifically in TOV112D-RES cells, but not in TOV112D-
WT cells.
We have also shown that saracatinib resistant 
cells express increased levels of both isoforms of the 
insulin receptor, IR:A and IR:B, as well as expressing 
increased levels of IGF2, the ligand for IR:A. Binding of 
IGF2 to IR:A has been reported to signal via the MAPK 
pathway, inducing a mitogenic response and driving 
cell cycle progression, mitosis and cell proliferation 
[42]. Interestingly, IGF signaling has previously been 
implicated in ovarian cancer progression and development, 
as well as resistance to targeted therapies and conventional 
chemotherapies [43–45]. Interestingly, increased SRC 
activity has been associated with resistance to anti-IGF-1R 
therapies. SRC and IGF-1R are reciprocally co-activated 
in high levels in non-small cell lung cancer (NSCLC) cells 
and inhibition of IGF-1R resulted in activation of SRC, 
and targeting SRC resensitzed cells to IGF-1R inhibition 
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[46]. Similarly, a combination of anti-IGF-1R and SRC 
therapies displayed enhanced antitumour activity in 
in vitro and in vivo models of rhabdomyosarcoma when 
compared to either drug alone [47].
Our data demonstrates different mechanisms by 
which MAPK signalling can become activated and result 
in resistance to SRC inhibition in ovarian cancer cells, 
highlighting the potential for combining SRC inhibitors 
with small molecule inhibitors of the MAPK pathway. 
We have shown that a combination of SRC and MEK 
inhibition synergistically inhibits the growth of ovarian 
cancer cell lines, and that MEK inhibition is sufficient 
Figure 4: Dual inhibition of MEK and SRC synergistically inhibits growth of ovarian cancer cells, and MEK 
inhibition can resensitize AZD0530 resistant cells. (A) 10 day colony formation assay showing sensitivity of TOV112D-WT and 
TOV112D-RES to increasing concentrations to increasing concentrations of AZD0530 as single agent or in combination with 100nM 
trametinib (GSK1120212). IC50 values are shown. (B) 10 day colony formation assay showing sensitivity of IGROV1-WT and IGROV1-
RES to increasing concentrations to increasing concentrations of AZD0530 as single agent or in combination with 100nM trametinib 
(GSK1120212). IC50 values are shown. (C) Combination index (CI) values for TOV112D-WT and TOV112D-RES, and IGROV1-WT 
and IGROV1-RES cells following treatment with various doses of a combination of saracatinib (AZD0530) and trametinib (GSK1120212). 
CI value <1 indicates drug synergy. P values are shown and were calculated using extra-sum of squares F-test. Data represented as mean 
± S.E.M n ≥ 3.
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to resenesitize ovarian cancer cell lines with acquired 
resistance to saracatinib (AZD0530).
The efficacy of combining SRC and MEK inhibitors 
has been previously investigated in various cancer 
cell lines. In melanoma cancer cells, a combination of 
MEK and SRC inhibition suppressed a MEK inhibitor 
driven invasive phenotype associated with epithelial 
to mesenchymal transition (EMT) [48]. Moreover, 
melanoma cells made resistant to the BRAF inhibitor 
vemurafinib, which acts upstream of MEK activation 
and signalling, exhibited activated SRC signalling 
in vitro and in vivo, and exhibited sensitivity to SRC 
inhibition by both dasatinib and saracatinib [49]. Growth 
of vemurafinib resistant patient derived xenografts 
(PDX) was suppressed following treatment with the 
SRC inhibitor dasatinib, and reduced metastases [49]. A 
combination of SRC and MEK inhibitors has also proved 
beneficial in the treatment of breast cancer cells, where 
the combination of selumetinib and saracatinib induced 
apoptosis and reduced the initiation of both dormant 
and metastatic tumour cells, leading to diminished 
lung metasteses, compared to saracatinib alone [50]. 
Furthermore, in non-small cell lung cancer cell lines, a 
combination of the MEK inhibitor PD0325901 with 
saracatininb (AZD0530) abrogated tumour growth, 
enhanced mesenchymal to epithelial transition (EMT) 
Figure 5: Schematic Model showing Activation of MAPK signalling Resulting in Resistance to AZD0530. Left: 
In saracatinib (AZD0530) sensitive cells, inhibition of SRC leads to a reduction in the ability of SRC to phosphorylate and activate 
downstream signalling pathways resulting in decrease proliferation, migration, invasion angiogenesis and cell death. Right: In saracatinib 
(AZD0530) resistant cells, increased expression and activation of HER2 and the insulin receptor drives the activation of the RAS-RAF-
MAPK pathway. Loss or reduction in the expression of the tumour suppressor gene NF1 also releases the negative regulation of RAS-RAF 
MAPK pathways allowing for MAPK induced cell survival and drug resistance. 
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and reduced cell migration and invasion [51]. Similar 
to our findings, recent work has also demonstrated the 
utility of combining SRC and MEK inhibitors in the 
ovarian cancer setting [52], where the combination 
of selumetinib and saracatinib abolished Rac-1 
mediated EMT of ovarian cancer cells. Furthermore, this 
drug combination suppressed tumour progression more 
effectively than either drug alone and prolonged survival 
of mice transplanted with intraperitoneal xenografts [52].
Here we have shown that MAPK activation, via 
various mechanisms, leads to resistance to saracatinib. 
Interestingly, MAPK activation has also been associated 
with resistance to platinum based chemotherapies in 
ovarian cancer [53–55], and notably, patient recruitment 
to the SAPPROC clinical trial was based on resistance 
to platinum therapy [18]. This highlights the potential 
issues which led to failure of saracatinib to provide any 
benefit to PFS of women receiving weekly paclitaxel in 
the treatment of ovarian cancer in the SAPPROC trial. 
We have shown that a combination of SRC and MEK 
inhibitors synergistically inhibits the growth of saracatinib 
resistant ovarian cancer cells, and so we propose that 
ovarian cancer patients are more likely to respond to 
SRC inhibition in combination with MEK inhibition. Our 
findings, to our knowledge, are the first to highlight the 
potential of combining SRC and MEK inhibitors in the 
treatment of platinum resistant ovarian cancer.
MATERIALS AND METHODS
Generation of novel cell lines
To generate a cell line with stable shRNA mediated 
knockdown of SRC, TOV112D cells were infected with 
lentivirus particles containing SRC specific shRNA, and 
selected in puromycin (Supplementary Information). 
Saracatinib (AZD0530) resistant cells were generated 
by culturing TOV112D and IGROV1 cells in 5 μM 
AZD0530 for 6 months. Once resistance to AZD0530 was 
established, TOV112D-RES and IGROV1-RES cells were 
maintained in 1 μM AZD0530. 
siRNA screening
A customised siRNA library targeting 178 tumour 
suppressor genes or genes whose loss of function was 
associated with cancer (Supplementary Table 1) was 
acquired using predesigned siRNA sequences (Qiagen). 
The library contained 3 independent siRNA sequences 
per gene and was provided in an arrayed format in 
96 well plates. Human foreskin fibroblasts (HFFs) 
cells were reverse transfected with the siRNA library 
(Qiagen) using Lipofectamine RNAiMax reagent (Life 
Technologies) (Supplementary Information). Cell viability 
was measured using Cell Titre Glo (Promega) 96 hours 
later. Results were median-centred, log transformed and 
normalised to scrambled siRNA negative control. Hits with 
robust z-scores of ±1 median absolute deviation (MAD) 
were carried forward for validation studies. 
Phospho-receptor tyrosine kinase array
Proteome Profiler Human Phospho-RTK Array Kit 
(RnD Systems) was performed according to manufacturer’s 
guidelines. Briefly, cell lysates were prepared in RIPA 
buffer from TOV112D-WT and TOV112D-RES cells, 
500μg of protein was incubated with each membrane. 
Densitometry analysis was performed using Image J (Fiji). 
Cell count assay
Human foreskin fibroblasts were reverse transfected 
with 10 nmol of gene specific siRNA (Qiagen) using 
Lipofectamine RNAiMax transfection reagent (Life 
Technologies), and 48 hours post transfection cells were 
trypsinized, counted and re-seeded into 6 well plates. 
24 hours later, media was replaced with increasing 
concentrations of AZD0530. After 10 days, cells were 
trypsinized and counted. The % survival fraction for a 
given dose/siRNA was calculated and dose-response 
curves were plotted.
Colony formation assays
Cells were seeded at predetermined densities, and 
24 hours later treated with increasing concentrations of 
saracatinib (AZD0530) or trametinib (GSK1120212), 
which was replenished every 3-4 days. Where appropriate, 
cells were transfected with 10 nmol of gene-specific 
targeting siRNAs (Qiagen) using Lipofectamine RNAiMax 
transfection reagent (Life Technologies) and 48 hours later, 
counted and seeded for colony formation. After 10 days, 
cells were washed with PBS, fixed for 10 minutes in 100% 
methanol, stained with crystal violet, and colonies were 
counted. The % survival fraction for a given dose/siRNA 
was calculated, and dose-response curves were plotted. 
Western blotting analysis
Cell pellets were lysed in RIPA buffer (50 mM 
Tris pH7.4, 140 mM NaCl, 1% NP40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate) containing 
phosphatase and protease inhibitor tablets (Roche). Cell 
pellets were lysed for 20 minutes on ice, after which 
nuclear and cellular debris was removed by centrifugation 
at 13,000 RPM for 10 minutes at 4oC. 10–20 μg of protein 
lysates were electrophoresed on NuPage precast gels 
(Invitrogen) and immunoblotted with anti-NF1 (Bethyl 
Antibodies), anti-phospho-SRC (Tyr416) (Cell Signalling 
Technology [CST]), anti-SRC (CST), phospho-ERK 
(CST), phospho-MEK (CST) total ERK (Cell signaling 
Technology), total MEK (CST), phospho-HER2 (CST), 
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total HER2 (Santa Cruz), phospho-Insulin Receptor/
IGF1R (CST), total insulin receptor (CST), phospho-FAK 
(Tyr925) (CST), total FAK (CST). As loading controls, 
vinculin (Santa Cruz) and beta-actin (Sigma) were used. 
Membranes were then incubated in anti-IgG-HRP (CST) 
and chemiluminescent detection (Luminata Cresendo, 
Millipore). 
Quantitative real-time PCR
RNA was extracted from cells using STAT-60 
Trizol. Chloroform was added and the RNA was extracted 
from the inorganic phase using isopropanol. cDNA was 
synthesized by reverse transcription using First strand 
DNA synthesis kit (Roche), and diluted to 25 ng/ul. 62.5 ng 
of each cDNA sample was used for each polymerase 
chain reaction, which was performed in triplicate for each 
sample. Relative mRNA levels of each gene of interest 
was quantified using Syber Green (Roche) as a flouresence 
marker, and analyzed using Light Cycler LC480 (Roche). 
Melt curve analysis was performed following each PCR 
run. Beta actin primers were used as a house keeping 
gene for normalization. Data was analysed using the 
ddCT method. qPCR primers sequences are defined in 
Supplementary Information 1. 
Statistical and drug relationship analysis 
Data are presented as the mean ± S.E.M from 
at least three independent experiments. P values were 
calculated using a Student’s t-test, or in the case of growth 
sensitivity assays significance was calculated by extra-
sum-of squares F-test (*p < 0.05, **p < 0.01, ***p < 0.001) 
using GraphPad Prism. Quantification of drug synergism 
and antagonism were conducted using CalcuSyn Software. 
Combination index (CI value) < 1 indicates drug synergy.
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